BACKGROUND: Ewing sarcoma (EWS) is rarely diagnosed as a second malignancy. We sought to describe a cohort of patients with secondary EWS and investigate if patient characteristics and survival differ between patients with secondary and primary EWS. PROCEDURE: Patients with EWS or peripheral primitive neuroectodermal tumor (PNET) reported to the Surveillance, Epidemiology, and End Results Program (SEER) database from 1973 to 2008 were evaluated based on primary or secondary tumor sequence. Overall survival was estimated by Kaplan-Meier methods and evaluated using the log-rank test. Competing risk analysis was used to describe risk of death due to malignancy rather than other causes. RESULTS: Fifty-eight cases of secondary EWS were reported, accounting for 2.1% of all EWS cases. The median latency from primary malignancy to secondary EWS was 64 months (range 1-282 months). 12.1% of patients with secondary EWS received radiation to the site of secondary tumor during therapy for their primary malignancy. Patients with secondary EWS were more likely to have axial tumors (77.4% vs. 62.5%; P = 0.03) and smaller tumors (75.0% vs. 48.2% <8 cm; P = 0.001). Five-year overall survival from diagnosis was inferior for patients with secondary compared to primary EWS (34.3% vs. 52.2%; P = 0.002). However, patients with secondary tumors were less likely than those with primary EWS to die from their malignancy [hazard ratio 0.44; 95% confidence interval (CI) 0.23-0.85]. CONCLUSIONS: Secondary EWS accounts for a minority of cases of EWS. Tumor size and site and patient survival differ among patients with primary and secondary EWS.
BACKGROUND:Ewing sarcoma (EWS) is rarely diagnosed as a second malignancy. We sought to describe a cohort of patients with secondary EWS and investigate if patient characteristics and survival differ between patients with secondary and primary EWS. PROCEDURE: Patients with EWS or peripheral primitive neuroectodermal tumor (PNET) reported to the Surveillance, Epidemiology, and End Results Program (SEER) database from 1973 to 2008 were evaluated based on primary or secondary tumor sequence. Overall survival was estimated by Kaplan-Meier methods and evaluated using the log-rank test. Competing risk analysis was used to describe risk of death due to malignancy rather than other causes. RESULTS: Fifty-eight cases of secondary EWS were reported, accounting for 2.1% of all EWS cases. The median latency from primary malignancy to secondary EWS was 64 months (range 1-282 months). 12.1% of patients with secondary EWS received radiation to the site of secondary tumor during therapy for their primary malignancy. Patients with secondary EWS were more likely to have axial tumors (77.4% vs. 62.5%; P = 0.03) and smaller tumors (75.0% vs. 48.2% <8 cm; P = 0.001). Five-year overall survival from diagnosis was inferior for patients with secondary compared to primary EWS (34.3% vs. 52.2%; P = 0.002). However, patients with secondary tumors were less likely than those with primary EWS to die from their malignancy [hazard ratio 0.44; 95% confidence interval (CI) 0.23-0.85]. CONCLUSIONS: Secondary EWS accounts for a minority of cases of EWS. Tumor size and site and patient survival differ among patients with primary and secondary EWS.
Authors: Sheri L Spunt; Carlos Rodriguez-Galindo; Christine E Fuller; JoAnn Harper; Matthew J Krasin; Catherine A Billups; Joseph D Khoury Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: G Bacci; S Ferrari; F Bertoni; S Rimondini; A Longhi; P Bacchini; C Forni; M Manfrini; D Donati; P Picci Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Grace E Kim; Barbara Beach; Julie M Gastier-Foster; Joyce L Murata-Collins; Jon M Rowland; Richard J O'Donnell; Robert E Goldsby Journal: Pediatr Blood Cancer Date: 2005-07 Impact factor: 3.167
Authors: Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Anna T Meadows; Debra L Friedman; Joseph P Neglia; Ann C Mertens; Sarah S Donaldson; Marilyn Stovall; Sue Hammond; Yutaka Yasui; Peter D Inskip Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Tara O Henderson; John Whitton; Marilyn Stovall; Ann C Mertens; Pauline Mitby; Debra Friedman; Louise C Strong; Sue Hammond; Joseph P Neglia; Anna T Meadows; Leslie Robison; Lisa Diller Journal: J Natl Cancer Inst Date: 2007-02-21 Impact factor: 11.816
Authors: Jessica Daley; Nathan Williams; Claudia M Salgado; Charles Schultz; Julia Meade; John Ozolek; Brock Lindsey; Kelly M Bailey Journal: J Pediatr Hematol Oncol Date: 2022-04-14 Impact factor: 1.170
Authors: Marion Cole; Shobha Parajuli; Douglas Laske; Lori Goldstein; Tara Morrison; Abir Mukherjee; Kathryn Tumelty; Eric Tetzlaff; Margaret von Mehren; Susan Inniss Journal: Am J Case Rep Date: 2014-07-10
Authors: Fabian Wolpert; Michael A Grotzer; Felix Niggli; Dieter Zimmermann; Elisabeth Rushing; Beata Bode-Lesniewska Journal: Sarcoma Date: 2016-07-25